Sherbrooke Park Advisers LLC Recursion Pharmaceuticals, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $215 Billion
- Q3 2025
A detailed history of Sherbrooke Park Advisers LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 29,684 shares of RXRX stock, worth $122,891. This represents 0.07% of its overall portfolio holdings.
Number of Shares
29,684
Previous 11,356
161.39%
Holding current value
$122,891
Previous $57.5 Million
152.1%
% of portfolio
0.07%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding RXRX
# of Institutions
361Shares Held
301MCall Options Held
7.71MPut Options Held
4.85M-
Vanguard Group Inc Valley Forge, PA39.8MShares$165 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33.5MShares$139 Million1.15% of portfolio
-
Baillie Gifford & CO24MShares$99.3 Million0.09% of portfolio
-
State Street Corp Boston, MA18.3MShares$75.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$71.7 Million0.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $747M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...